Yissum - Research Development Company of the Hebrew University

NOVEL METHOD TO EXPAND AND GET HIGHER CONCENTRAION AND PROLIFERATION OF CHICKEN EMBRYONIC FIBROBLASTS CELLS

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

A new method for culturing contact-dependent cells in suspension
A unique cell line of chicken embryonic fibroblasts (CEFs) that can reach extremely high cell densities in suspensions, was developed using this method
Project ID : 6-2018-4673

Description of the technology

Background

Chicken embryonic fibroblasts (CEFs) are commonly used for the production of vaccines and are a source material for cultured meat. Fibroblasts are contact-dependent limiting their large-scale production to carrier beads capable of reaching only 5-6 million cells/ml.

Our Innovation

We developed a method that allows the culture of chicken embryonic fibroblasts (CEF’s) in suspension. We produced a sub-clone of the commonly used DF-1 line which can uniquely reach extremely high cells densities in suspension cultures. The cell line is a continuous line of chicken embryo. The cells are free of endogenous sequences related to avian sarcoma and leukosis viruses and have normal fibroblastic morphology. The cells have higher proliferation rate and also can be sub-cultured infinite number of times.The expected increase in yield is up to 40-fold in comparison to current growing methods

Applications for use

Chicken Embryonic Fibroblasts (CEFs) are commonly used in the industry, and as so, methods for improving large-scale industrial cell production are of need, specifically for vaccine production

The proposed technology can be used by pharmaceutical and biotechnology companies to develop human and veterinary viral and therapeutic vaccines.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Yaakov Nahmias
HUJI, School of Computer Science and Engineering
Bio-Engineering

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Research / Development tools

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.